Showing results (2451-2460 of 2,542) with videos related to

Sort By:
Pageof 255
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 29, 2026
The Erosion of a Pillar of Public Health: ACIP's Role and the Future of U.S. Vaccine Policy Post-June 2025Edwin J Asturias, Robert Schechter, H Keipp Talbot, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2017
Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27Patrick N A Harris, Nouri L Ben Zakour, Leah W Roberts, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
The Journal of Experimental Medicine|May 29, 2013
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemiaEdward W Roberts, Andrew Deonarine, James O Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2019
Detection of Epidemic Scarlet Fever Group A Streptococcus in AustraliaMark J Walker, Stephan Brouwer, Brian M Forde, et al.
Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.
Blood|April 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissionsSasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, et al.
Blood|July 28, 2018
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AMLMathijs A Sanders, Edward Chew, Christoffer Flensburg, et al.
The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.
Pageof 255